tetano
Editor, Senior Moderator
Arch Virol
. 2021 Jul 19.
doi: 10.1007/s00705-021-05152-5. Online ahead of print.
The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection
Jiulue Hu[SUP] 1 [/SUP], Jelena Stojanović[SUP] 2 [/SUP], Saman Yasamineh[SUP] 3 [/SUP], Pooneh Yasamineh[SUP] 4 [/SUP], Sathish Kumar Karuppannan[SUP] 5 [/SUP], Mohammed Junaid Hussain Dowlath[SUP] 5 [/SUP], Hamed Serati-Nouri[SUP] 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there is no effective therapeutic approach for treating SARS-CoV-2 infections. MicroRNAs (miRNAs) have been recognized to target the viral genome directly or indirectly, thereby inhibiting viral replication. Several studies have demonstrated that host miRNAs target different sites in SARS-CoV-2 RNA and constrain the production of essential viral proteins. Furthermore, miRNAs have lower toxicity, are more immunogenic, and are more diverse than protein-based and even plasmid-DNA-based therapeutic agents. In this review, we emphasize the role of miRNAs in viral infection and their potential use as therapeutic agents against COVID-19 disease. The potential of novel miRNA delivery strategies, especially EDV™ nanocells, for targeting lung tissue for treatment of SARS-CoV-2 infection is also discussed.
. 2021 Jul 19.
doi: 10.1007/s00705-021-05152-5. Online ahead of print.
The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection
Jiulue Hu[SUP] 1 [/SUP], Jelena Stojanović[SUP] 2 [/SUP], Saman Yasamineh[SUP] 3 [/SUP], Pooneh Yasamineh[SUP] 4 [/SUP], Sathish Kumar Karuppannan[SUP] 5 [/SUP], Mohammed Junaid Hussain Dowlath[SUP] 5 [/SUP], Hamed Serati-Nouri[SUP] 6 [/SUP]
Affiliations
- PMID: 34278528
- DOI: 10.1007/s00705-021-05152-5
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there is no effective therapeutic approach for treating SARS-CoV-2 infections. MicroRNAs (miRNAs) have been recognized to target the viral genome directly or indirectly, thereby inhibiting viral replication. Several studies have demonstrated that host miRNAs target different sites in SARS-CoV-2 RNA and constrain the production of essential viral proteins. Furthermore, miRNAs have lower toxicity, are more immunogenic, and are more diverse than protein-based and even plasmid-DNA-based therapeutic agents. In this review, we emphasize the role of miRNAs in viral infection and their potential use as therapeutic agents against COVID-19 disease. The potential of novel miRNA delivery strategies, especially EDV™ nanocells, for targeting lung tissue for treatment of SARS-CoV-2 infection is also discussed.